The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

Table 1 Baseline characteristics for the total number of study subjects and according to treatment group

	Total (n = 364)	Placebo (n = 188)	Galantamine (n = 176)	P value^a
Age	68 (8.8)	69 (8.6)	68 (9.0)	0.13
Sex, female	49	54	43	0.04
Hypertension	44	45	43	0.62
Diabetes	7	7	7	0.98
Elevated cholesterol	34	35	32	0.59
Smoking	9	10	7	0.46
ADAS-Cog/MCI	15 (7.0)	14 (6.9)	15 (7.2)	0.56
Whole brain (ml)	1,089 (124)	1,081 (124)	1,097 (123)	0.22
Hippocampal volume (ml)	5.85 (0.9)	5.78 (0.9)	5.93 (0.9)	0.11

Data presented as means (standard deviation) or percentages. ADAS-Cog, Alzheimer’s Disease Assessment Scale – cognitive subscale; MCI, mild cognitive impairment. ^aP values for differences in means or percentages between patients treated with placebo and those treated with galantamine.

ISSN: 1758-9193